ClinVar Miner

Submissions for variant NM_000153.4(GALC):c.850G>A (p.Gly284Ser) (rs377274761)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Centre for Mendelian Genomics,University Medical Centre Ljubljana RCV000415223 SCV000492714 likely pathogenic Leukodystrophy; Status epilepticus; Global developmental delay; Seizures; EEG abnormality; Nystagmus; Hemiparesis; Strabismus; Progressive visual loss; Amblyopia; Intrauterine growth retardation; Small for gestational age; Breech presentation; Neonatal hypoglycemia; Developmental regression; EMG abnormality; EMG: axonal abnormality; Loss of ability to walk; Dysmyelinating leukodystrophy 2015-10-28 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000588587 SCV000695673 pathogenic Galactosylceramide beta-galactosidase deficiency 2016-11-08 criteria provided, single submitter clinical testing Variant summary: The GALC c.850G>A (p.Gly284Ser) variant involves the alteration of a conserved nucleotide. 4/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 1/120666 control chromosomes at a frequency of 0.0000083, which does not exceed the estimated maximal expected allele frequency of a pathogenic GALC variant (0.0022361). This variant has been reported in multiple affected individuals with evidence of co-segregation. Functional assay showed variant with 5% of WT activity (De Gasperi et al 1996). Taken together, this variant is classified as pathogenic.
Centre for Mendelian Genomics,University Medical Centre Ljubljana RCV000588587 SCV001369176 likely pathogenic Galactosylceramide beta-galactosidase deficiency 2016-01-01 criteria provided, single submitter clinical testing This variant was classified as: Likely pathogenic.
Invitae RCV000588587 SCV001416954 pathogenic Galactosylceramide beta-galactosidase deficiency 2020-10-03 criteria provided, single submitter clinical testing This sequence change replaces glycine with serine at codon 284 of the GALC protein (p.Gly284Ser). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and serine. This variant is present in population databases (rs377274761, ExAC 0.001%). This variant has been observed in individual(s) with Krabbe disease or its clinical features (PMID: 8940268, 22520351, 29286531). It has also been observed to segregate with disease in related individuals. This variant is also known as p.G268S in the literature. ClinVar contains an entry for this variant (Variation ID: 374024). This variant has been reported to affect GALC protein function (PMID: 27638593, 8940268). For these reasons, this variant has been classified as Pathogenic.
Counsyl RCV000588587 SCV000791856 likely pathogenic Galactosylceramide beta-galactosidase deficiency 2017-05-25 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.